AMH and breast cancer: This systematic review and meta-analysis evaluates AMH decline and the prevalence of low (AMH <1 ng/mL) and very low (<0.5 ng/mL) ovarian reserve in BC survivors <40 years old, 12–24 months post-chemotherapy, to quantify the gonadotoxic impact of BC treatments.